Due to the diversity of tumor-promoting cell types within CRC, current medical techniques need to achieve precise modulation of CCL5 expression in a particular cell type (Table 1), requiring treatments that combine multiple inhibitory measures targeting both cancer and stromal cells to produce effective tumor treatments. The gene discussed is CCL5; the disease is neoplasm.